FDA OKs Synchrony Medical’s LibAirty for at-Home Respiratory Relief

Synchrony Medical, a company focused on respiratory care, has earned U.S. Food and Drug Administration (FDA) 510(k) clearance for its LibAirty airway clearance system.

LibAirty, according to the company, is the first airway clearance system that synchronizes controlled breathing with targeted chest compressions. It addresses a critical need for patients living with chronic lung diseases such as chronic obstructive pulmonary disease (COPD), bronchiectasis, and cystic fibrosis.

The technology was inspired by the principles of Autogenic Drainage, an airway clearance technique that usually needs extensive patient training and support from a respiratory therapist. LibAirty adapts this with a patient app that offers breathing guidance and a wearable vest that delivers synchronized chest compressions—directing airflow to thoroughly clear hard-to-reach small airways.

The technology was developed in collaboration with experts from the Sheba Medical Center.

“For millions of people, effective airway clearance is vital for reducing symptoms, improving quality of life, slowing disease progression, and preventing infections that often lead to costly hospitalizations,” said Dr. Moshe Ashkenazi, co-founder of Synchrony Medical and Senior Pediatric Pulmonologist at Sheba Medical Center. “Unfortunately, many patients still lack access to effective airway clearance solutions they can use routinely at home,”

Synchrony Medical CEO Anat Shani said earning FDA clearance for LibAirty is a pivotal moment in the company’s mission to transform respiratory care.

“This milestone will allow us to help improve patients’ lives and overall respiratory health,” Shani said. “Building on this achievement, we are establishing our US headquarters in New Jersey and are actively preparing for a limited rollout of LibAirty in select sites later in 2025.”